Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $65.1 million.

  • Tonix Pharmaceuticals Holding's Net Cash Flow rose 17025.11% to $65.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.2 million, marking a year-over-year increase of 66336.3%. This contributed to the annual value of $73.8 million for FY2024, which is 17807.75% up from last year.
  • Tonix Pharmaceuticals Holding's Net Cash Flow amounted to $65.1 million in Q3 2025, which was up 17025.11% from -$6.4 million recorded in Q2 2025.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's Net Cash Flow peaked at $70.5 million during Q4 2024, and registered a low of -$48.2 million during Q1 2023.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median Net Cash Flow value was -$2.9 million (recorded in 2024), while the average stood at $6.5 million.
  • As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Net Cash Flow skyrocketed by 29302.79% in 2024, and later plummeted by 12042.16% in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Net Cash Flow (Quarter) stood at $17.9 million in 2023, then surged by 293.03% to $70.5 million in 2024, then decreased by 7.66% to $65.1 million in 2025.
  • Its Net Cash Flow stands at $65.1 million for Q3 2025, versus -$6.4 million for Q2 2025 and $32.9 million for Q1 2025.